Designing ofa phase 2, multicenter, randomized, placebo-controlled, double-blind study to assess the efficacy and safety of nipocalimab, an fcrn inhibitor, in adults with primary sjogren's syndrome
ARTHRITIS & RHEUMATOLOGY（2023）
Key words
FcRn, Nipocalimab, Sjogren's Syndrome
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined